Member Info for Walkley

.....and the report is only $4,900!

We have had four, what I thought were, very positive RNSs in the past few months 1) $62m BARDA contract to develop Ridinilazole 2) Deal on Ridinilazole for Latin America. 3) Buying Discuva � which should lead to more candidate drugs to complement our existing two. 4) Break through results from Ezutromid trial; yet the market cap is still below �200m. Whilst we, or most of us, on this board are bullish on Summit why hasn�t the market got as excited as we are?

and now back to 219 on google and HSBC can sell for 210p. Wonder how many stop losses were activated by that spike down?

Price on Google 111p!!! WTF

Can I second that!

So now that we aren’t just a two trick pony, will the market wake up to Summit’s potential. Happy Christmas and prosperous New Year to long term Summiteers.

If the BOD have any sense then they might look at being a bit more generous with the dividend!

Thanks - you learn something everyday - And forget 5 other things!

From Panmure Gordons website: "Summit Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications [sic], for which there are no existing or only inadequate therapies." Are "indications" a medical technical term or does predictive text strike again.

Average number of shares traded in US according to Google is 200,000 (ADR x 5 ) average in UK 37,000. Both tiny quantities but quite a difference.

Well perhaps something exciting is about to happen, or it may be wishful thinking. Reading too much into one word may be a mistake! But sold some boring, dividend paying, house builder to buy another 3,000 today at a price I didn't expect to be available after the good news on the US grant for Ridinilazole

Yes Sheepy, I am hopefiul that the recent RNS: "Summit announces signing of revenue sharing agreement with the Wellcome Trust for cdi antibiotic Ridinilazole" was a deck clearing exercise before the big announcement of a deal on Ridinilazole. Whilst we have the funds in place for phase 3 (includng the grant) it is is probable that they want to concentrate resources on the DMD programme.

Top of the rising share prices! And much more soon!

From the Muscular Dystrophy UK web site: "Another potential therapy for DMD is to raise the levels of utrophin protein, as a functional substitute for dystrophin. The potential treatment has been developed in the laboratory of Professor Kay Davies in Oxford. Despite excellent results in animal models, the first clinical trial in healthy volunteers of a first generation drug SMT C1100 lead to the delivery of insufficient amount of the drug to the muscles. SMT C1100 has since been improved and has recently successfully met its primary endpoint of safety and tolerability in a phase Ib clinical trial in DMD patients. On the basis of these findings, a second phase I trial tested the drug in boys with DMD when they are on a particular diet. The results showed that a balanced proportion of fats, proteins and carbohydrates increase the levels of SMT C1100 in the blood. A phase II open-label clinical trial to evaluate the safety and longer-term benefits of SMT C1100 on muscle health and function is currently underway. There is now considerable effort ongoing in Oxford to develop second-generation drugs that have the potential to raise utrophin levels further. One such potential drug, SMT022357, has been shown to be distributed along the length of muscle fibres in the mdx mouse. Owing to its physical and chemical properties SMT022357 is likely to be more stable in the body than SMT C1100." Hadn't appreciated that the next generation of these drugs was this far on. Sounds positive.

So if they had raised $80m by a share issue that would have been seriously diluting - that most of it was a grant was surely excellent. We now have a strong well financed operation. Look forward to some valuations of the business if one or both programmes are successful.

Disappointed as everyone else by the short term effect of the fund raising but surely this strengthens Summit's negotiating position with regards to RDZ . I still think a deal is likely before phase 3 testing of RDZ starts but now not at any price.

My view is that the BARDA award is the first step and a joint venture or other agreement with a major pharma is the second step which will be finalised any day now, or at least by Christmas. The prospect of an imminent deal would make it difficult to discuss the BARDA award in a conference call Of course I have no information, and no contacts within Summit, but given the importance of the DMD programme and the commitment to the science behind it, it would seem sensible to get the funds to further develop this programme from a product that is almost ready to go. Even big companies would want to be able to justify to themselves and their shareholders spending significant sums on a new drug such as RDZ and the BARDA award should help. I would hope that the prospect of significant returns was exciting fund managers and getting them to add a few thousand Summit shares to their portfolios!

Thought so, every silver lining needs its cloud! You don't think big pharma could be accused of saying "We cant do what you want [develop new antibiotics] without some cash from the government" do you?

Gosh! Unless I have misunderstood, Pomander's comment could be read as positive news. Are you suggesting that Summit might actually make something out of RDZ? Seriously though, the BARDA endorsement should encourage a major pharma to pay substantially to bring RDZ to market. Am I alone at being disappointed by Summit being considered worth only £200m by the market?

I read "any patent on an invention that is conceived or first reduced to practice under the contract" as meaning any new patents - RDZ patents are old ones created before this award.